Abstract Search

10.12. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients

SE Nissen , AM Lincoff , D Brennan , KK Ray , D Mason , JJP Kastelein , PD Thompson , P Libby , L Cho , J Plutzky , HE Bays , PM Moriarty , V Menon , DE Grobbee , MJ Louie , CF Chen , N Li , L Bloedon , P Robinson , M Horner , WJ Sasiela , J McCluskey , D Davey , P Fajardo-Campos , P Petrovic , J Fedacko , W Zmuda , Y Lukyanov , SJ Nicholls , CLEAR Outcomes Investigators Nicholls

Brief summary: In this double-blind, randomized, placebo-controlled trial, bempedoic acid (Nexletol) reduced the incidence of a composite cardiovascular.Comment: Bempedoic acid is an ATP citrate lyase inhibitor. ATP citrate lyase catalyses the conversion of citrate to acetyl-CoA, the fundamental substrate required for the synthesis of cholesterol and fatty acids. By inhibiting the cholesterol synthesis pathway, bempedoic acid reduces intra-hepatic LDL-C....

1 shares

ESPE Yearbook of Paediatric Endocrinology

10.12. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients

BiosciAbstracts